Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole



Status:Recruiting
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:19 - Any
Updated:2/20/2019
Start Date:September 17, 2018
End Date:May 31, 2020
Contact:Alisa Peinhardt
Email:apeinhardt@uabmc.edu
Phone:205-934-9661

Use our guide to learn which trials are right for you!

SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial

This is a prospective, multi-center, randomized, open-label parallel arm study involving
patients with proven or probable invasive endemic fungal infection to ascertain the
pharmacokinetics, safety, efficacy, tolerability and health economics of oral
SUBA-itraconazole compared to conventional itraconazole. Patients will receive randomized
open-label study drug (SUBA-itraconazole or conventional itraconazole) over a 42 day period
and then continue therapy until Day 180. Patients will be stratified based on clinically
reported infection with the human immunodeficiency virus (HIV).

This is a prospective, multi-center, randomized, open-label parallel arm study involving
patients with proven or probable invasive endemic fungal infection to ascertain the
pharmacokinetics, safety, efficacy, and tolerability of oral SUBA-itraconazole or
itraconazole. Patients will receive randomized open-label study drug (either SUBA-
itraconazole 130 mg twice daily or itraconazole 200 mg twice daily) over a 42-day period and
then continue on their assigned open-label therapy until day 180.

The study sample size will be 80 evaluable patients - target enrollment (three arms:
approximately 40 histoplasmosis, 20 coccidioidomycosis, 20 other endemic fungal infections).

Inclusion Criteria:

1. Male and female patients age > 18 years who have given written informed consent to
participate

2. Patients with a proven or probable endemic mycosis (Histoplasma, Coccidioides,
Paracoccidioides, Blastomyces, Sporothrix, Talaromyces marneffei (formerly Penicillium
marneffei) according to current EORTC/MSG (Mycoses Study Group) criteria, including
patients who:

- Are immunosuppressed, including as a result of HIV/AIDS

- Have had a heart, lung or bone marrow transplant

- Have had chemotherapy for cancer

- Are otherwise normal hosts

Exclusion Criteria:

1. Significant liver dysfunction as evidenced by at least 5 times greater than upper
limits of normal baseline ALT (alanine aminotransferase) , AST (aspartate
aminotransferase), alkaline phosphatase, or total bilirubin.

2. Use of an alternative antifungal therapy (IV or oral) for more than 14 days for this
infection.

3. Evidence of CNS (central nervous system) infection.

4. Unable to take PO medications.

5. Female patients who are lactating or pregnant.

Women should be:

1. Postmenopausal for 1 year,

2. Post-hysterectomy or bilateral oophorectomy,

3. If of child bearing potential have a negative β-HCG (human chorionic
gonadotropin) at screening and using highly effective method of birth control
throughout course of study or remain abstinent for duration of study.

6. Documented intolerance, allergy or hypersensitivity to an azole.

7. Inability to comply with study treatment, study visits, and study procedures.

8. Known history of congestive cardiac failure on medical treatment, fungal endocarditis,
or other causes of ventricular dysfunction that may outweigh the benefit of
itraconazole.

9. Patients with active TB (tuberculosis)

10. Concurrent use of astemizole, rifampin/rifampicin, rifabutin, ergot alkaloids, long
acting barbiturates, carbamazepine, pimozide, quinidine, neostigmine, terfenadine,
ketoconazole, valproic acid, or St. John's wort in the 5 days prior to first
administration of study drug.

11. Any known or suspected condition of the patient that may jeopardize adherence to the
protocol requirements or impede the accurate measurement of efficacy.

12. Treatment with any investigational agent in the 30 days prior to study entry.

13. Patients unlikely to survive 30 days (including severe fungal disease defined by
systolic blood pressure (SBP) < 90; hypoxia < 60).

14. Patients with body weight < 40 kg.
We found this trial at
6
sites
Chicago, Illinois 60612
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Peter G Pappas, MD
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Marisa Miceli, MD
Phone: 734-647-9830
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Madison, Wisconsin 53792
(608) 263-2400
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
1 Shields Ave
Sacramento, California 95616
(530) 752-1011
University of California-Davis As we begin our second century, UC Davis is poised to become...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Andrej Spec, MD
Phone: 314-747-1922
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials